Abstract: The invention relates to a method of determining equine NT-proBNP, or fragments thereof, comprising the steps of: providing an equine sample, contacting the sample with at least one antibody which specifically binds to equine NT-proBNP, and determining the presence and/or concentration of the equine NT-proBNP or fragments thereof existing in the sample.
Abstract: The present invention is in the area of coagulation analysis and relates to antibodies which bind specifically to an immune complex of prothrombin fragment F2/F1+2 and an F2/F1+2 neoepitope-specific antibody fragment, and to the preparation and the use thereof in methods for determining F2/F1+2.
Abstract: A monoclonal antibody that binds specifically to the SNAP motif and to the CLIP tag comprising CDRs with the amino acid sequences SEQ ID Nos. 3, 4, 5, and 8, 9, 10.
Type:
Grant
Filed:
November 26, 2012
Date of Patent:
July 14, 2015
Assignee:
FRAUNHOFER-GESELLSCHAFT ZUR FÖRDERUNG DER ANGEWANDTEN FORSCHUNG E.V.
Inventors:
Stefan Barth, Katharina Kolberg, Christiane Püttmann, Severin Schmies
Abstract: The present invention relates to a diagnostic test for inflammatory endothelial dysfunctions in pregnant women. Particularly, the present invention relates to a method of diagnosing or evaluating the risk of contracting an inflammatory endothelial dysfunction of the maternal compartment comprising the following steps: a) detecting the plasma levels of long pentraxin PTX3 in blood samples taken from a pregnant woman; b) comparing the PTX3 plasma level data, obtained according to step a), with statistically significant PTX3 plasma level data of normal pregnant population.
Type:
Grant
Filed:
December 18, 2006
Date of Patent:
July 14, 2015
Assignee:
Humanitas Mirasole S.p.A.
Inventors:
Alberto Mantovani, Cecilia Garlanda, Andrea Doni, Irene Cetin
Abstract: The present invention provides a tag peptide comprising an amino acid sequence represented by the following formula (I): X1-Tyr-X2-Gly-Gln-X3??(I) (wherein X1, X2 and X3 are the same or different and each represent any amino acid residue) and an antibody against the tag peptide. By combined use of the tag peptide and antibody of the present invention, a system that enables proteins expressed from cloned genes to be highly purified in an inexpensive and easy manner can be established.
Abstract: Compositions and methods comprising proteins that bind specifically to adalimumab are disclosed herein. Adalimumab is a monoclonal antibody specific for the cytokine TNF-? and was developed to treat TNF-? mediated inflammatory diseases. In one aspect of the instant invention, the binding proteins are antibodies directed toward adalimumab. These antibodies, including binding fragments thereof, can be used in a clinical setting as well as for research and development. For example, these anti-adalimumab antibodies can be employed to neutralize adalimumab.
Abstract: Disclosed is an assay (method) to quantify the amounts of catecholamine-O-methyltransferase (COMT) protein in samples, such as extracts from cell cultures, body fluids, tissues, and environmental samples. It uses novel agents (anti-NE, COMT-NE, or COMT-epitope-NE) in combination with two previously described agents (anti-COMT and COMT) in a competitive ELISA system to achieve this aim.
Type:
Grant
Filed:
September 8, 2009
Date of Patent:
January 6, 2015
Assignee:
The University of Hong Kong
Inventors:
Shu Leong Ho, Wing Lok Ho, David Boyer Ramsden
Abstract: A protein used as a biomarker for diagnosing IgA nephropathy and TGBM (thin-glomerular-basement-membrane) using urine through a target proteomics method. A diagnosis biomarker protein and a kit for diagnosing IgA nephropathy and TGBM and predicting progress of the nephropathy in advance using the protein are provided. The degree of the progression of the disease can be grasped by detecting IgA nephropathy and TGBM, enabling early diagnosis and confirming progress from the patient's urine. In addition, a monoclonal antibody produced based on the diagnosis biomarker protein can be used for an immunoassay kit (ELISA, antibody coated tube test, lateral-flow test, potable biosensor). The monoclonal antibody is used in early diagnosis and progression detection of IgA nephropathy and development of a novel drug for the purpose of treatment.
Type:
Grant
Filed:
September 30, 2009
Date of Patent:
January 6, 2015
Assignee:
Kyungpook National University Industry-Academic Cooperation Foundation
Inventors:
Moon Chang Baek, Pyong Gon Moon, Yong Lim Kim
Abstract: The present invention includes assays and kits for detecting the assembly of an RNA binding protein-RNA complex and for detecting the activity of an RNA binding protein.
Type:
Grant
Filed:
March 10, 2006
Date of Patent:
September 2, 2014
Assignee:
The Trustees of the University of Pennsylvania
Inventors:
Gideon Dreyfuss, Lili Wan, Elizabeth Ottinger
Abstract: A composition comprising a conjugate of an anti-idiotype antibody specifically binding to a CDR region of a parent antibody and method of using polyclonal human serum immunoglobulin of class E, G, M, or A, and the use of said composition as a standard in an immunoassay is presented.
Type:
Grant
Filed:
November 16, 2007
Date of Patent:
August 19, 2014
Assignee:
Hoffmann-La Roche Inc.
Inventors:
Kay-Gunnar Stubenrauch, Rudolf Vogel, Uwe Wessels
Abstract: A method for determining the amount of NT-proBNP in blood samples from animals. The method includes detecting degradation products of NT-proBNP by various methods, including using antibodies, kits and device.
Type:
Grant
Filed:
August 4, 2011
Date of Patent:
July 15, 2014
Assignee:
Idexx Laboratories, Inc.
Inventors:
Mahalakshmi Yerramilli, Michael Atkinson, Murthy V. S. N. Yerramilli
Abstract: The present invention is related to the obtaining of modified antibodies by means of DNA recombinant technology from the murine monoclonal antibody P3 (MAb P3), produced by the hybridoma cell line deposited under Budapest Treaty with accession number ECACC 94113026, and from its anti-idiotype murine monoclonal antibody 1E10(MAbai 1E10), produced by the hybridoma cell line with deposit number ECACC 97112901, with the objective of achieving monoclonal antibodies which preserve the biological function of specifically binding the antigen of the original antibodies, but being at the same time less immunogenic.
Type:
Grant
Filed:
March 19, 2009
Date of Patent:
June 24, 2014
Assignee:
Centro de Inmunologia Molecular (CIM)
Inventors:
Cristina Maria Mateo De Acosta Del Rio, Josefa Lombardero Valladares, Lourdes Tatiana Roque Navarro, Alejandro Lopez Requena
Abstract: The present invention pertains to a method for in vitro prognosticating and/or diagnosing cerebral cerebral malaria, wherein said method comprises a step of detecting non-erythroid spectrin or fragments thereof, and/or antibodies directed against non-erythroid spectrin, in a biological sample. Reagents and kits for performing this method are also disclosed.
Type:
Grant
Filed:
March 30, 2007
Date of Patent:
April 1, 2014
Assignees:
Institut Pasteur, Universite Pierre et Marie Curie (Paris 6)
Abstract: The present invention relates to functional, modified glucose-galactose binding proteins (GGBPs), that have a greater melting temperature (Tm) than a reference GGBP. The present invention also relates to biological sensors, e.g., glucose sensors, comprising these thermostable GGBPs. The present invention also relates to nucleic acids encoding these thermostable GGBPs.
Type:
Grant
Filed:
April 20, 2007
Date of Patent:
January 7, 2014
Assignee:
Becton, Dickinson and Company
Inventors:
Terry J. Amiss, Erin M. Gill, Douglas B. Sherman
Abstract: The invention relates to an in vitro method for detecting pulmonary arterial hypertension (PAHT), or the risk of developing PAHT, which includes determining the presence and/or amount of anti-tenascin C antibodies in a biological sample from a patient.
Type:
Grant
Filed:
April 10, 2009
Date of Patent:
December 17, 2013
Assignees:
Assistance Publique-Hopitaux de Paris, Universite Paris Descartes, Universite Paris-Sud 11
Inventors:
Luc Mouthon, Marc Humbert, Mathieu Tamby
Abstract: The present invention provide reagents and methods of using the reagents, for example, on automated staining devices, that facilitate detection of two or more antigens in a sample simply and efficiently.
Abstract: The present invention provides, as a novel diagnosis marker for type 1 diabetes mellitus, a type 1 diabetes mellitus diagnostic composition comprising alanyl-tRNA synthetase, glycyl-tRNA synthetase, asparaginyl-tRNA synthetase, or tryptophanyl-tRNA synthetase, a diagnostic kit comprising the same, and a diagnostic method using the same. The composition, the kit, and the method, according to the present invention, may be used for early diagnosis and confirmed diagnosis of type 1 diabetes mellitus because type 1 diabetes mellitus can be easily diagnosed from a patient sample.
Type:
Grant
Filed:
August 5, 2011
Date of Patent:
October 22, 2013
Assignees:
Seoul National University Hospital, SNU R&DB Foundation
Inventors:
Sang Gyu Park, Kyong Soo Park, Sunghoon Kim